Compare Amphastar Pharmaceuticals Inc (AMPH) vs UiPath Inc (PATH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs UiPath Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while UiPath Inc trades at $11.75 (market cap $6.05B). The key difference: UiPath Inc is far larger — about 7.3× Amphastar Pharmaceuticals Inc's market cap, and UiPath Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | PATH | |
|---|---|---|
Market Cap | $826.08M | $6.05B |
Sector | Health | Technology |
52-Week High | $30.81 | $19.29 |
52-Week Low | $16.87 | $9.38 |
Enterprise Value | $1.22B | $4.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
UiPath (PATH) trades at $11.68, down 1.02% on the day, with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growing from $1.43B in 2025 to projected $1.7B in 2026, while narrowing losses from -$74M to projected $327M profit. Recent product launches like Maestro Case expand enterprise automation capabilities. Analyst consensus price target sits at $13.33, representing 14% upside potential from current levels.
PATH presents a compelling growth story with strong revenue expansion and path to profitability, though elevated valuation multiples and competitive pressures warrant caution. The stock's current pullback offers entry opportunity for investors bullish on enterprise automation adoption, with key risks including execution on AI strategy and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
